### **Overview** MedPlus Health Services Ltd is a leading organized pharmacy retail chain in India and the **second-largest pharmacy retailer by revenue and store count**. Founded in 2006 in Hyderabad with 48 stores, the company has evolved into a dominant omnichannel healthcare player, combining physical retail, e-pharmacy, private-label manufacturing, and integrated diagnostics. As of September 2025, MedPlus operates **4,930 stores** across **13 Indian states and 1 union territory**, covering over **750 cities**, including all major metros and a rapidly growing presence in tier-2 and smaller towns. --- ### **Core Business Model & Differentiation** MedPlus operates a **vertically integrated, omnichannel healthcare platform** that blends: - **Retail pharmacy and FMCG sales** - **Wholesale and distribution** - **Private-label manufacturing (pharma and non-pharma)** - **In-house technology infrastructure** - **Diagnostic services (currently focused in South India)** Its **key competitive advantages** include: - **100% pharmaceutical market coverage** – Unlike online-only players focused on chronic care (~37% of the market), MedPlus serves both **acute and chronic segments** due to its physical store network. - **Sub-2-hour hyperlocal delivery** – Enabled by dense store clusters, reducing last-mile costs and enhancing customer convenience. - **Proprietary technology platform** – Powers omnichannel operations, inventory forecasting, and data analytics to optimize supply chain and customer engagement. - **Customer acquisition cost advantage** – Stores act as **branding hubs**, significantly lowering marketing spend. - **Backward integration** – Owns end-to-end supply chain, from sourcing to distribution and private-label manufacturing. --- ### **Expansion Strategy & Store Network** MedPlus pursues a **"deeper than wider" cluster-based expansion strategy**, prioritizing **market penetration in existing geographies** before entering new ones. - **Store Count:** - **4,930 stores (Sep 2025)**, up from 4,552 in Sep 2024 and 4,407 in Sep 2024. - Net addition of **378 stores in the past 12 months**. - **Geographic Reach:** - Operates in **13 states and 1 UT** (Puducherry, with 5 stores), covering over 750 cities. - Added **600 new stores in five years**; future plans include entering **Madhya Pradesh and Chhattisgarh**. - **New Markets:** - Entered **Delhi-NCR (Noida)** in late 2024 with three stores, marking presence in all top seven Indian cities. - Selective, cautious expansion in **Kerala**, with a “wait and watch” approach to ensure profitability. - **Store Economics:** - Average store size: ~530 sq. ft. - Mature stores achieve **10% EBITDA margin** within 2.5 years; breakeven in **3–6 months**. - Stores in **tier-2 and beyond generate higher margins** due to lower rent and operating costs. --- ### **Private Label & Product Strategy** A **core growth engine**, private label products are central to MedPlus’s margin expansion and customer loyalty strategy. - **Private Label Portfolio (As of Oct 2025):** - **Over 1,450 SKUs** across pharmaceuticals and FMCG (nutrition, wellness, personal care). - Includes **chronic, sub-chronic, OTC, and acute medications**, branded under MedPlus for quality assurance. - **Pricing & Value:** - Priced **50–80% below MRP** by eliminating intermediaries and marketing expenses. - Manufactured in facilities that also supply major pharmaceutical companies, ensuring **high quality and trust**. - Targets price-sensitive customers, including those who shop at **Jan Aushadhi Stores**, but with **superior quality assurance**. - **Revenue Contribution:** - **~28% of pharmacy GMV** (May 2025), up from ~7.9% in early FY24. - **~18.4% of total revenue** (Nov 2024), trending upward. - Management aims for long-term growth, though expects share to stabilize **below 90%** due to regulatory and market constraints. - **Marketing & Uptake:** - **49/year pharmacy subscription** in select regions (e.g., Hyderabad) offers 50–80% discounts on 400+ private label drugs. - Strong customer adoption: **~220,000 subscribers** in Hyderabad by Sep 2023. --- ### **Omnichannel & Technology Edge** MedPlus leverages its **in-house technology platform** to strengthen its omnichannel model. - **Capabilities:** - Mobile app and website (medplusmart.com) for online orders. - **Click & Pick** and **Home Delivery** (under 2 hours) enabled by hyperlocal stores. - Online services expanded to **over 2,158 pin codes** (FY23). - **Technology Infrastructure:** - Over **150 in-house engineers** working on open-source, microservices-based architecture. - Hybrid cloud setup (private + public) ensures **scalability and flexibility**. - Smart POS system enables **real-time inventory visibility** across stores and warehouses, supporting cross-selling (pharmacy + diagnostics). - **Customer Retention:** - Higher retention among **omnichannel users** (both online and offline). - Technology supports **personalized engagement**, order history, and appointment booking (for diagnostics). --- ### **Supply Chain & Logistics** MedPlus maintains a **resilient, automated supply chain** to ensure high fill rates and low distribution costs. - **Warehousing:** - Added **10 new warehouses** in FY25, moving from **1 to 2–3 per state** to enhance local logistics. - Focus on **densification in existing markets** rather than new geographies. - Warehouses automated to **reduce costs and improve efficiency**. - **Sourcing:** - Sources pharmaceuticals **directly from manufacturers**, bypassing distributors, which **boosts gross margins**. - **Inventory Management:** - Mature stores hold **~39 days of inventory**, warehouses **30–35 days**. - Data-driven forecasting improves stock availability and reduces shortages. --- ### **Diagnostics Business** MedPlus is building a **vertically integrated diagnostics ecosystem** to complement its pharmacy offerings. - **Current Presence:** - Operates in **Hyderabad** with: - 4 full-service centers - 8 level-2 centers - 100+ sample collection points - Expansion underway in **Chennai, Bangalore, Pune, Kolkata, Nagpur, Bhubaneswar**. - **Business Model:** - **Subscription-based services** (e.g., 110,000+ subscribers as of late 2023), offering discounts and co-pay options. - Integrated with pharmacy and digital platform for **seamless patient journey**. - **Financials:** - Diagnostics revenue grew from ₹74.76 crore (FY22) to ₹305.54 crore (FY23). - Segment **nearing breakeven**, with declining losses and strong customer uptake. - Total CAPEX: ~₹110 crore invested. --- ### **Growth Drivers** - **Shift from unorganized to organized retail** – MedPlus is capturing this transition, especially in tier-2+ cities (50% of expansion). - **Aging population** – Rising demand for chronic medication, doorstep delivery, and integrated health services. - **Private label adoption** – Improves margins and deepens customer loyalty. - **Geographic expansion** – Focus on underserved areas with populations as low as 10,000. - **FMCG diversification** – Expanding into **nutrition, wellness, and daily essentials**, increasing revenue per store. --- ### **Financial & Operational Highlights (FY23 & Beyond)** - **Revenue (FY23):** ₹4,527 crore (retail), ₹306 crore (diagnostics) - **Growth:** 20.8% YoY revenue increase in FY23 - **Margins:** Gross margin ~21.94% (FY23), EBITDA ₹3,117 crore - **Store Expansion:** 1,144 new stores opened in FY23 (record high), with net additions continuing at ~1,000+ per year. - **Funding:** Self-funded through **internal cash flows**; minimal debt; strong balance sheet provides flexibility for debt/equity raises if needed. - **Private Label Pricing:** MedPlus private-label drugs cost **one-fifth** of branded generics to stock, improving inventory efficiency. --- ### **Challenges & Competitive Landscape** - **Competition:** - Online players (e.g., PharmEasy, 1mg) willing to operate at losses. - Large retail chains using scale for discounts. - Government-backed **Jan Aushadhi Stores** offering deep discounts on generics. - **Regulatory Constraints:** - Price controls on essential drugs limit promotional flexibility. - **Operational Hurdles:** - **20–30% employee attrition**, as retail jobs are often entry-level. - Supply chain disruptions in remote areas earlier addressed by warehouse densification.